Literature DB >> 27193687

An obligatory role for neurotensin in high-fat-diet-induced obesity.

Jing Li1,2, Jun Song1,2, Yekaterina Y Zaytseva2,3, Yajuan Liu2, Piotr Rychahou1,2, Kai Jiang2, Marlene E Starr1, Ji Tae Kim1,2, Jennifer W Harris1,2, Frederique B Yiannikouris4, Wendy S Katz4, Peter M Nilsson5,6, Marju Orho-Melander5, Jing Chen7,8, Haining Zhu7,8, Timothy Fahrenholz2,3,9, Richard M Higashi2,3,9, Tianyan Gao2,7, Andrew J Morris10, Lisa A Cassis4, Teresa W-M Fan2,3,9, Heidi L Weiss2,11, Paul R Dobner12, Olle Melander5,6, Jianhang Jia2,7, B Mark Evers1,2.   

Abstract

Obesity and its associated comorbidities (for example, diabetes mellitus and hepatic steatosis) contribute to approximately 2.5 million deaths annually and are among the most prevalent and challenging conditions confronting the medical profession. Neurotensin (NT; also known as NTS), a 13-amino-acid peptide predominantly localized in specialized enteroendocrine cells of the small intestine and released by fat ingestion, facilitates fatty acid translocation in rat intestine, and stimulates the growth of various cancers. The effects of NT are mediated through three known NT receptors (NTR1, 2 and 3; also known as NTSR1, 2, and NTSR3, respectively). Increased fasting plasma levels of pro-NT (a stable NT precursor fragment produced in equimolar amounts relative to NT) are associated with increased risk of diabetes, cardiovascular disease and mortality; however, a role for NT as a causative factor in these diseases is unknown. Here we show that NT-deficient mice demonstrate significantly reduced intestinal fat absorption and are protected from obesity, hepatic steatosis and insulin resistance associated with high fat consumption. We further demonstrate that NT attenuates the activation of AMP-activated protein kinase (AMPK) and stimulates fatty acid absorption in mice and in cultured intestinal cells, and that this occurs through a mechanism involving NTR1 and NTR3 (also known as sortilin). Consistent with the findings in mice, expression of NT in Drosophila midgut enteroendocrine cells results in increased lipid accumulation in the midgut, fat body, and oenocytes (specialized hepatocyte-like cells) and decreased AMPK activation. Remarkably, in humans, we show that both obese and insulin-resistant subjects have elevated plasma concentrations of pro-NT, and in longitudinal studies among non-obese subjects, high levels of pro-NT denote a doubling of the risk of developing obesity later in life. Our findings directly link NT with increased fat absorption and obesity and suggest that NT may provide a prognostic marker of future obesity and a potential target for prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27193687      PMCID: PMC5484414          DOI: 10.1038/nature17662

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  64 in total

1.  Amphetamine-elicited striatal Fos expression is attenuated in neurotensin null mutant mice.

Authors:  Jim Fadel; Paul R Dobner; Ariel Y Deutch
Journal:  Neurosci Lett       Date:  2006-04-24       Impact factor: 3.046

2.  Neurotensin receptor-1 and -3 complex modulates the cellular signaling of neurotensin in the HT29 cell line.

Authors:  Stéphane Martin; Valérie Navarro; Jean Pierre Vincent; Jean Mazella
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

Review 3.  Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.

Authors:  K G M M Alberti; P Zimmet; J Shaw
Journal:  Diabet Med       Date:  2006-05       Impact factor: 4.359

Review 4.  AMPK: positive and negative regulation, and its role in whole-body energy homeostasis.

Authors:  D Grahame Hardie
Journal:  Curr Opin Cell Biol       Date:  2014-09-26       Impact factor: 8.382

Review 5.  Neurotensin and neurotensin receptors.

Authors:  J P Vincent; J Mazella; P Kitabgi
Journal:  Trends Pharmacol Sci       Date:  1999-07       Impact factor: 14.819

6.  Specific localisation of neurotensin to the N cell in human intestine by radioimmunoassay and immunocytochemistry.

Authors:  J M Polak; S N Sullivan; S R Bloom; A M Buchan; P Facer; M R Brown; A G Pearse
Journal:  Nature       Date:  1977-11-10       Impact factor: 49.962

7.  SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission.

Authors:  R Steinberg; P Brun; M Fournier; J Souilhac; D Rodier; G Mons; J P Terranova; G Le Fur; P Soubrié
Journal:  Neuroscience       Date:  1994-04       Impact factor: 3.590

8.  mTORC1 inhibition increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON.

Authors:  Jing Li; Jianyu Liu; Jun Song; Xiaofu Wang; Heidi L Weiss; Courtney M Townsend; Tianyan Gao; B Mark Evers
Journal:  Am J Physiol Cell Physiol       Date:  2011-04-20       Impact factor: 4.249

Review 9.  AMPK as a mediator of hormonal signalling.

Authors:  Chung Thong Lim; Blerina Kola; Márta Korbonits
Journal:  J Mol Endocrinol       Date:  2009-07-22       Impact factor: 5.098

10.  Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality.

Authors:  Olle Melander; Alan S Maisel; Peter Almgren; Jonas Manjer; Mattias Belting; Bo Hedblad; Gunnar Engström; Ute Kilger; Peter Nilsson; Andreas Bergmann; Marju Orho-Melander
Journal:  JAMA       Date:  2012-10-10       Impact factor: 56.272

View more
  79 in total

1.  Absence of neurotensin attenuates intestinal dysbiosis and inflammation by maintaining Mmp7/α-defensin axis in diet-induced obese mice.

Authors:  Jing Li; Xian Li; Jun Song; Baoxiang Yan; Stephanie A Rock; Jianhang Jia; Jinpeng Liu; Chi Wang; Todd Weiss; Heidi L Weiss; Tianyan Gao; Ashfaqul Alam; B Mark Evers
Journal:  FASEB J       Date:  2020-05-02       Impact factor: 5.191

2.  Diverse actions of the modulatory peptide neurotensin on central synaptic transmission.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Eur J Neurosci       Date:  2018-02-28       Impact factor: 3.386

3.  Targeting the gut to treat obesity and its metabolic consequences: view from the Chair.

Authors:  K A Sharkey
Journal:  Int J Obes Suppl       Date:  2016-11-16

Review 4.  Neuroendocrinology in 2016: Neuroendocrine control of metabolism and reproduction.

Authors:  Manuel Tena-Sempere
Journal:  Nat Rev Endocrinol       Date:  2017-01-06       Impact factor: 43.330

5.  Lipid malabsorption from altered hormonal signaling changes early gut microbial responses.

Authors:  Natalie A Terry; Lucie V Ngaba; Benjamin J Wilkins; Danielle Pi; Nishi Gheewala; Klaus H Kaestner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-06-28       Impact factor: 4.052

6.  Obesity: Neurotensin inhibition prevents weight gain.

Authors:  Sarah Crunkhorn
Journal:  Nat Rev Drug Discov       Date:  2016-06-17       Impact factor: 84.694

7.  Obesity: Could 13 amino acids combat obesity?

Authors:  Tim Geach
Journal:  Nat Rev Endocrinol       Date:  2016-05-27       Impact factor: 43.330

Review 8.  Role of central neurotensin in regulating feeding: Implications for the development and treatment of body weight disorders.

Authors:  Laura E Schroeder; Gina M Leinninger
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-12-27       Impact factor: 5.187

9.  Neurotensin/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of Tumor-Associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells.

Authors:  Pei Xiao; Xinxin Long; Lijie Zhang; Yingnan Ye; Jincheng Guo; Pengpeng Liu; Rui Zhang; Junya Ning; Wenwen Yu; Feng Wei; Jinpu Yu
Journal:  Oncoimmunology       Date:  2018-03-13       Impact factor: 8.110

10.  Conformational Changes in Tyrosine 11 of Neurotensin Are Required to Activate the Neurotensin Receptor 1.

Authors:  Fabian Bumbak; Trayder Thomas; Billy J Noonan-Williams; Tasneem M Vaid; Fei Yan; Alice R Whitehead; Shoni Bruell; Martina Kocan; Xuan Tan; Margaret A Johnson; Ross A D Bathgate; David K Chalmers; Paul R Gooley; Daniel J Scott
Journal:  ACS Pharmacol Transl Sci       Date:  2020-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.